NASDAQ · Biotechnology

Immutep Limited (IMMP) Stock

$0.44 +0.90% NASDAQ: IMMP Healthcare

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.

Valuation

MetricValue
Price$0.44
Market Cap$64.36M
P/E Ratio-0.94
P/B Ratio0.80
P/S Ratio13.32
EPS (TTM)$-0.42
52-Week High$3.53
52-Week Low$0.29
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-69.20%
ROA-57.01%
ROCE-122.41%
Gross Margin-522.59%
Operating Margin-2520.00%
Net Margin-1220.00%
Debt/Equity0.02
Current Ratio2.97

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$0$4.0M$4.0M$5.0M
Operating Profit$-32.0M$-34.0M$-78.0M$-88.0M$-126.0M
Net Profit$-30.0M$-32.0M$-40.0M$-43.0M$-61.0M
EPS$-0.49$-0.37$-0.44$-0.36$-0.42
Op Margin-820.0%-19920.0%-2216.1%-2293.3%-2506.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$82.0M$102.0M$147.0M$202.0M$157.0M
Total Liabilities$9.0M$8.0M$11.0M$12.0M$13.0M
Cash$60.0M$80.0M$123.0M$162.0M$67.0M
Borrowings$3.0M$2.0M$1.0M$2.0M$2.0M

Latest News

Immutep Granted New US Patent for Cancer Treatment Methods MT Newswires · Jul 14, 2026 Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor GlobeNewswire · Jul 14, 2026 Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight GlobeNewswire · Jul 13, 2026 Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004 GlobeNewswire · Jul 13, 2026 Immutep Shares Rise After Maxim Group Upgrade MT Newswires · Jun 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-18.0M$-30.0M$-36.0M$-35.0M$-62.0M
Investing Cash Flow$0$0$0$-23.0M$-39.0M
Financing Cash Flow$10.0M$-2.0M$-4.0M$-5.0M$0
Net Cash Flow$34.0M$19.0M$43.0M$38.0M$-94.0M
Free Cash Flow$-18.0M$-30.0M$-36.0M$-36.0M$-62.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA-0.11
FCF Yield-78.26%
Quick Ratio2.97
Interest Coverage-3137.06
Return 1Y-73.01%
Return 3Y-79.82%
Return 5Y-87.88%

Ownership

Insiders Held0.01%
Institutions Held2.43%
Institutions Float Held2.43%
Institutional HolderSharesReport Date
Blackrock Inc.810,9262026-03-31
UBS Group AG748,8112026-03-31
Meridian Wealth Management, LLC449,5502026-03-31
Two Sigma Investments, LP124,7602026-03-31
Citadel Advisors Llc78,1742026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACHV $6.66 +2.94% -4.63 $683.71M 0.00%
ALLO $1.95 +2.63% -2.17 $673.05M 0.00%
CABA $2.71 -2.17% -2.23 $441.88M 0.00%
CADL $10.59 +0.09% -11.10 $775.93M 0.00%
CAPR $3.93 -5.76% -50.70 $227.59M 0.00%

About Immutep Limited

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Immutep Limited is headquartered in AU.

Immutep Limited (IMMP) stock trades at $0.44 with a market capitalization of $64.36M. The stock is valued at a price-to-earnings (P/E) ratio of -0.94, price-to-book of 0.80, price-to-sales of 13.32. Over the past 52 weeks the stock has ranged between $0.29 and $3.53, and currently trades 87.5% below its 52-week high.

On profitability, Immutep Limited generates a return on equity (ROE) of -69.20%, return on capital employed of -122.41%, an operating margin of -2520.00%, a net profit margin of -1220.00%.

Official website: www.immutep.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides